BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Novartis AG (NVS) Breast Cancer Drug Rejected Despite Being Hailed as a "Breakthrough"


3/21/2013 8:15:18 AM

Novartis drug Afinitor, expected to be a big seller for the Swiss group, has been rejected by Britain's health cost agency NICE due to uncertainty over its survival benefits in breast cancer. Novartis said it was "extremely disappointed" by Thursday's draft decision from the National Institute for Health and Clinical Excellence. Afinitor, or everolimus, is the first in a class known as mTOR inhibitors to be approved for post-menopausal women with advanced hormone-receptor positive, HER2-negative breast cancer. "While the independent appraisal committee acknowledged that everolimus may offer a step change in treatment by restoring sensitivity of the tumor to hormone therapy, the evidence highlighted uncertainty relating to how much the treatment extends overall survival," said NICE CEO Andrew Dillon. "Using the most appropriate estimates, the committee concluded that everolimus is not a cost-effective treatment option for the NHS (National Health Service)."

Read at Reuters
Read at Telegraph
Read at News Release
Read at News Release


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->